期刊
REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
卷 50, 期 3, 页码 296-300出版社
SOC BRASILEIRA MEDICINA TROPICAL
DOI: 10.1590/0037-8682-0433-2016
关键词
Chagas Treatment; Benznidazole; Access; Latin America
资金
- MSF
After more than one century since its discovery, Chagas disease is still extremely prevalent in 21 Latin American countries. Chagas disease is one of the most concerning public health problems in Latin America; the overall cost of CD treatment is approximately 7 billion United States dollars per year and it has a strong social impact on populations. Little progress has been made regarding the access to diagnosis and treatment at the primary health care level, calling into question the current policies to ensure the right to health and access to essential medications. In this article, diverse dimensions of access to treatment for Chagas disease are reviewed, illustrating the present state of benznidazole medication in relation to global production capacity, costs, and needs. The findings are based on an investigation requested by Medecins Sans Frontieres Brazil through a consultancy in 2015, aiming to estimate the current costs of benznidazole production.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据